Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
Lester J, Escriu C, Khan S, Hudson E, Mansy T, Conn A, Chan S, Powell C, Brock J, Conibear J, Nelless L, Nayar V, Zhuo X, Durand A, Amin A, Martin P, Zhang X, Pawar V. Lester J, et al. Among authors: escriu c. BMC Cancer. 2021 May 7;21(1):515. doi: 10.1186/s12885-021-08096-w. BMC Cancer. 2021. PMID: 33962574 Free PMC article.
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Banna GL, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A, Addeo A, Signori A, McKenzie H, Escriu C, Barone G, Chan S, Hicks A, Bainbridge H, Pinato DJ, Ottensmeier C, Gomes F. Banna GL, et al. Among authors: escriu c. Int Immunopharmacol. 2022 Sep;110:108985. doi: 10.1016/j.intimp.2022.108985. Epub 2022 Jun 28. Int Immunopharmacol. 2022. PMID: 35777264 Free article.
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.
Schwartzberg LS, Horinouchi H, Chan D, Chernilo S, Tsai ML, Isla D, Escriu C, Bennett JP, Clark-Langone K, Svedman C, Tomasini P; Oncotype SEQ® Study Investigators and Program Team. Schwartzberg LS, et al. Among authors: escriu c. NPJ Precis Oncol. 2020 Jun 24;4:15. doi: 10.1038/s41698-020-0118-x. eCollection 2020. NPJ Precis Oncol. 2020. PMID: 32596507 Free PMC article.
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.
Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, Cortellini A, Addeo A, Escriu C, McKenzie H, Barone G, Murray L, Bhatnagar G, Pinato DJ, Ottensmeier C, Gomes F, Banna GL. Anpalakhan S, et al. Among authors: escriu c. Int J Mol Sci. 2023 Jan 16;24(2):1746. doi: 10.3390/ijms24021746. Int J Mol Sci. 2023. PMID: 36675262 Free PMC article.
24 results